IV peramivir may get swift approval

There's been a considerable amount of speculation about which of the new flu vaccine and antiviral technologies now in the clinic will benefit from the swine flu outbreak and the outcry it has provoked for better medicines. Most of that speculation has centered on future pandemics--but BioCryst may not have to wait that long. While HHS Secretary Kathleen Sebelius was being grilled about shortages of vaccines and antivirals, she voiced a strong desire to see the intravenous formulation of BioCryst's antiviral peramivir approved quickly. BioCryst report